从总的随机对照试验数据中获得未报告的小组特定生存率
Oguzhan Alagoz1, Prianka Singh2, Matthew Dixon2
1Department of Industrial and Systems Engineering and Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI, USA.
概括
这项研究引入了一个新的框架,用于从随机对照试验 (RCT) 中估计子组生存曲线. 该方法准确地重建了生存数据,有助于卫生技术评估和元分析.
科学领域:
- 生物统计学 生物统计学
- 卫生经济学 卫生经济学
- 临床试验分析
背景情况:
- 随机对照试验 (RCT) 往往缺乏子组特定的生存数据,阻碍了详细的健康技术评估.
- 小组分析对于了解特定患者群体的治疗效果至关重要.
- 现有的总量数据限制需要新的分析方法.
研究的目的:
- 开发和验证一个分析框架,从汇总的RCT数据中提取未报告的小组特定生存曲线.
- 为了使特定子组的间接比较和成本效益分析.
- 提高RCT数据对细微的临床和经济评估的有用性.
主要方法:
- 开发了一个优化模型,假设指数分布的子组生存持续时间.
- 使用子组RMSTs的加权平均值,估计的受限制平均存活时间 (RMST).
- 从森林地块中纳入的危险比率,以将试验组中的子组危险率与试验组联系起来.
- 验证了现实生活瘤学RCT和合成数据集的模型.
主要成果:
- 该模型准确地预测了合成 (97%,87%) 和现实 (80%,85%) 试验案例中的高百分比子组的95%置信区间内的中位生存率和RMST.
- 预测的生存曲线与报告的卡普兰-梅尔曲线一致,在合成数据中97%的时间和现实数据中71%的时间.
- 该框架在从综合数据中重建子组生存分布方面表现强.
结论:
- 拟议的分析框架提供了一种可扩展和有效的方法,用于从汇总的RCT结果中提取子组特定的生存数据.
- 这种方法促进了特定子组的间接比较,成本效益分析和元分析,如果这些数据否则无法获得.
- 该研究增强了现有的RCT数据的价值,用于更细致的健康经济和临床研究.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
633
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
542
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
542
01:21Cancer Survival Analysis
634
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
634
01:09Censoring Survival Data
511
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
511
01:24Kaplan-Meier Approach
547
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
547
01:15Assumptions of Survival Analysis
388
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
388
01:12Hazard Ratio
554
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
554